drugset / Trial / NCT02587689
Phase I/II Study of Anti-Mucin1 (MUC1) CAR T Cells for Patients With MUC1+ Advanced Refractory Solid Tumor
Phase 1/2
Unknown
20 enrolled
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Hefei Binhu Hospital · collabThe First People's Hospital of Hefei · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine whether autologous T cells bearing chimeric antigen receptor that can specifically recognize (Mucin 1) MUC1 is safe and effective for patients with relapsed or refractory solid tumor.
Timeline
- Start
- 2015-10
- Primary completion
- 2017-10
- Completion
- 2018-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Anti-MUC1 CAR-T cells | Cell therapy | — | — |